Press releases
Thermo Fisher Scientific Acquires Viral Vector Manufacturing Business from Novasep
Expanded global capacity addresses growing demand for cell and gene therapy
Novasep to sell its chromatography equipment division to Sartorius
• A disposal aligned with Novasep’s core strategy
• An opportunity for Novasep’s chromatography equipment division to accelerate its growth by joining an established leader in the sector
The French bioproduction sector announces the creation of Campus Biotech Digital, a platform unique in the world for bioproduction training
An ambitious goal to develop the skills necessary for health independence
Novasep invests €6.5 million to expand capacity and increase flexibility in an API manufacturing workshop at its Chasse-sur-Rhône site (69 – France)
Novasep announces a €6.5 million investment to upgrade an API manufacturing workshop at its Chasse-sur-Rhône site (69 - France)
Novasep and Handl Therapeutics announce signature of a gene therapy product development and manufacturing agreement
This agreement covers the development and manufacturing of an Adeno-Associated Virus (AAV) based gene therapy drug candidate for the treatment of neurodegenerative diseases
Sensorion and Novasep announce signature of a gene therapy product development and manufacturing agreement
• Agreement covers the development and manufacturing of AAV vectors, a key step for Sensorion’s gene therapy programs
• Agreement secures drug product development and manufacturing capacity for the Company’s Otoferlin program
• Gene therapy could revolutionize the treatment of genetic inner ear disorders
Frontier Biotech chooses Novasep HPLC chromatography columns and skids for peptide purification on its Nanjing (China) site
Novasep, a leading supplier of services and technologies for the life sciences industry, announces Frontier Biotechnologies Inc. (“Frontier Biotech”) chooses Novasep Prochrom® HPLC chromatography columns and skids for its Nanjing (China) site.
Coronavirus: NOVASEP partners with ASTRAZENECA to produce Covid-19 Oxford vaccine for Europe
Novasep will produce the active substance of the vaccine in its Belgian facilities
NOVASEP and LYSOGENE Announce their New Collaboration for Development and Production of GM1 Gangliosidosis Gene Therapy Product
This agreement covers the manufacturing of the Adeno-Associated Virus (AAV)